Actrims News Today

Mitzi Joi Williams, MD, of Joi Life Wellness Multiple Sclerosis (MS) Center, lists challenges in recruiting and retaining minority populations for clinical trials and discusses ways to ensure clinical trial accessibility.

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 22.02.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immun...

Issuer: Immunic, Inc. / Key word(s): Conference/Study Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023

Data demonstrate potential of Manual Dexterity Test and Konectom smartphone-based technology in measuring MS disease progressionRetrospective analysis applying machine learning, artificial intelligence

Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous

Regulatory News: GeNeuro (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such

-- Presentations will feature analyses from the pivotal Phase 3 study of UPLIZNA, including the relationship between B-cell subsets and NMOSD attacks -- Horizon Therapeutics plc (Nasdaq: HZNP) today

New real-world data show MAVENCLAD (cladribine tablets) had lower annualised relapse rates and longer time to first relapse and time to switch than fingolimod, dimethyl fumarate and teriflunomide

Phase II post-hoc data show evobrutinib reduced acute and chronic inflammation processes in the central nervous system that may be early indicators of MS disease progression Additional data

Full analysis of Phase 3b NOVA study provides insights on efficacy of every six-week dosing with natalizumab as compared to the approved every four-week dosingReal-world analysis shows significantly lower